content_image/172863.jpg
## OTHER CHARGES INCOME, NET 

<img src='content_image/172863.jpg'>

## Princeton Property Sale 

On March 18, 2008, we completed the sale of our 158-acre Princeton research center to the Princeton HealthCare System. Gross proceeds from the sale were $62.5 million and net proceeds after off sets, commissions and fees totaled approximately $60 million. The gain on sale was $29 million and is included in “Restructuring and other charges (income)” in the consolidated statements of income for the year ended December 31, 2008. The gain on sale was reduced by the sale-leaseback deferral described below. 

As part of the sale, we entered into a sale-leaseback under which certain of the buildings sold to the Princeton HealthCare System were leased back to us for a maximum period up to approximately three years. The leaseback was accounted for as an operating lease and the present value of the lease payments was deferred as part of the gain on sale. At the time of the sale, we recorded a deferred gain in the amount of $6.7 million. This amount was being recognized as a reduction of rent expense over the term of the lease. During the third quarter of 2009, we moved into our new research and development facility and as a result we exited our leases with the Princeton HealthCare System. Th  e event resulted in a net gain of $2.3 million since the amounts we deferred as part of the gain on sale assumed a longer lease period. 

## Sodium Sulfate Assets Sale 

In February 2008, we completed the sale of Foret’s non-cogeneration sodium sulfate assets. We recognized a gain on sale of these assets of $3.6 million, which is included in “Restructuring and other charges (income)” in the consolidated statements of income for the year ended December 31, 2008. Net proceeds from the transaction were $16.7 million. 

We did not complete the sale of the sodium sulfate co-generation facility at the time we sold the other sodium sulfate assets noted above. We completed the sale of this asset in the third quarter of 2009 for a gain of $1.0 million. 

## Legal Matters 

During the year ended December 31, 2010, we recorded $1.5 million of net charges primarily related to a legal settlement associated with the U.S. hydrogen peroxide matter in our Industrial Chemicals segment. 

During the year ended December 31, 2009, we recorded an approximate charge of $21.0 million in connection with the resolution of a regulatory 

matter in our Industrial Chemicals Segment. We also recorded a charge of $3.3 million related to the settlement of a legal matter in our Industrial Chemicals segment and $5.6 million of other charges primarily representing settlements with state authorities for property claims and adjustments. 

During the year ended December 31, 2008, we reached an agreement in principle to settle a federal class action lawsuit, alleging violations of antitrust laws involving our hydrogen peroxide product in our Industrial Chemicals segment in the amount of $10.0 million. 

See Note 18 for further details. 

## Environmental Charges, Net at Operating Sites 

During the years ended December 31, 2010, 2009 and 2008 we recorded $14.2 million, $20.2 million and $16.2 million of net charges, respectively, related to environmental remediation at continuing operating sites. See Note 10 for additional details. 

## Other, Net 

In the second quarter of 2010, our Agricultural Products segment acquired certain rights relating to an herbicide compound still under development. We expensed $5.7 million for these rights. 

In 2006, our Agricultural Products segment entered into a development agreement with a third-party company, whereby we were given the right to develop further one of the third party company’s products in certain geographic markets. This development agreement, representing a fungicide project, was terminated by the Company in 2008. In 2007, our Agricultural Products segment entered into a collaboration and license agreement with another third-party company for the purpose of obtaining certain technology and intellectual property rights. In 2007, we acquired further rights under the development agreement, and in 2009 we extended our rights under the collaboration and license agreement. We have recorded charges of $0.5 million, $2.0 million and $1.0 million in 2010, 2009 and 2008, respectively, under these agreements representing payments to acquire and extend our rights under these agreements. 

Remaining other charges for 2010, 2009 and 2008 primarily represents the accrual of interest associated with the European Commission fi ne recorded during the year ended December 31, 2006. See Note 18. 

